ES2904492T3 - Terlipresina para el tratamiento del síndrome hepatorrenal tipo 1 - Google Patents

Terlipresina para el tratamiento del síndrome hepatorrenal tipo 1 Download PDF

Info

Publication number
ES2904492T3
ES2904492T3 ES15791430T ES15791430T ES2904492T3 ES 2904492 T3 ES2904492 T3 ES 2904492T3 ES 15791430 T ES15791430 T ES 15791430T ES 15791430 T ES15791430 T ES 15791430T ES 2904492 T3 ES2904492 T3 ES 2904492T3
Authority
ES
Spain
Prior art keywords
terlipressin
patient
days
administration
serum creatinine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15791430T
Other languages
English (en)
Spanish (es)
Inventor
Khurram Jamil
Stephen Chris Pappas
Jim Potenziano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Pharmaceuticals Ireland Ltd
Original Assignee
Mallinckrodt Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Pharmaceuticals Ireland Ltd filed Critical Mallinckrodt Pharmaceuticals Ireland Ltd
Application granted granted Critical
Publication of ES2904492T3 publication Critical patent/ES2904492T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1024—Counting particles by non-optical means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
ES15791430T 2014-10-24 2015-10-22 Terlipresina para el tratamiento del síndrome hepatorrenal tipo 1 Active ES2904492T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068357P 2014-10-24 2014-10-24
US201562151384P 2015-04-22 2015-04-22
PCT/US2015/056861 WO2016065117A1 (en) 2014-10-24 2015-10-22 Method of treating patients with hepatorenal syndrome type 1

Publications (1)

Publication Number Publication Date
ES2904492T3 true ES2904492T3 (es) 2022-04-05

Family

ID=54478246

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15791430T Active ES2904492T3 (es) 2014-10-24 2015-10-22 Terlipresina para el tratamiento del síndrome hepatorrenal tipo 1
ES21205752T Active ES2987577T3 (es) 2014-10-24 2015-10-22 Terlipresina para el tratamiento del síndrome hepatorrenal tipo 1

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES21205752T Active ES2987577T3 (es) 2014-10-24 2015-10-22 Terlipresina para el tratamiento del síndrome hepatorrenal tipo 1

Country Status (15)

Country Link
US (2) US10335452B2 (enExample)
EP (3) EP3209317B1 (enExample)
JP (4) JP6673915B2 (enExample)
CN (2) CN107206049B (enExample)
AU (1) AU2015335855A1 (enExample)
CA (1) CA2965325A1 (enExample)
DK (2) DK3209317T3 (enExample)
ES (2) ES2904492T3 (enExample)
FI (1) FI3978074T3 (enExample)
HR (1) HRP20220225T1 (enExample)
HU (1) HUE058066T2 (enExample)
PL (2) PL3209317T3 (enExample)
PT (2) PT3978074T (enExample)
SI (1) SI3209317T1 (enExample)
WO (1) WO2016065117A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2678833C2 (ru) 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
AU2015335855A1 (en) * 2014-10-24 2017-05-18 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US20200046798A1 (en) * 2014-10-24 2020-02-13 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US20210290725A1 (en) * 2014-10-24 2021-09-23 Mallinckrodt Pharmaceuticals Ireland Limited Method of treating patients with hepatorenal syndrome type 1
MA46586A (fr) 2016-10-21 2019-08-28 Chiasma Inc Compositions de terlipressine et leurs procédés d'utilisation
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN110251469B (zh) * 2019-07-31 2021-11-09 南京康舟医药科技有限公司 一种醋酸特利加压素制剂及其制备方法
CA3159575A1 (en) * 2019-10-30 2021-05-06 Mallinckrodt Hospital Products IP Unlimited Company Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure
WO2023183339A1 (en) * 2022-03-22 2023-09-28 Ocelot Bio, Inc. Selective vasopressin receptor agonist for end-stage liver disease
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GB0617581D0 (en) * 2006-09-07 2006-10-18 Ucl Business Plc Biomarkers for assessing liver function
US20080221551A1 (en) * 2007-03-09 2008-09-11 Flowmedica, Inc. Acute kidney injury treatment systems and methods
EP2175874A2 (en) 2007-08-14 2010-04-21 Ferring B.V. Use of peptidic vasopressin receptor agonists
CN104330574B (zh) * 2008-11-10 2017-04-12 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
MX355507B (es) 2009-03-09 2018-04-19 Bioatla Llc Proteinas mirac.
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
KR20130026504A (ko) * 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
CN103254295A (zh) * 2013-05-31 2013-08-21 青岛国大生物制药股份有限公司 特利加压素的制备方法
AU2015335855A1 (en) * 2014-10-24 2017-05-18 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
EP3981420B1 (en) 2026-08-12
PL3978074T3 (pl) 2024-08-12
CN107206049B (zh) 2021-12-07
JP2022171795A (ja) 2022-11-11
DK3978074T3 (da) 2024-05-13
HUE058066T2 (hu) 2022-06-28
JP2019199485A (ja) 2019-11-21
PT3978074T (pt) 2024-05-13
ES2987577T3 (es) 2024-11-15
DK3209317T3 (da) 2022-02-07
EP3981420A1 (en) 2022-04-13
FI3978074T3 (fi) 2024-05-20
PT3209317T (pt) 2022-01-19
JP7346494B2 (ja) 2023-09-19
JP6673915B2 (ja) 2020-03-25
CA2965325A1 (en) 2016-04-28
EP3209317A1 (en) 2017-08-30
EP3978074B1 (en) 2024-03-06
WO2016065117A1 (en) 2016-04-28
US20160113994A1 (en) 2016-04-28
CN114028536A (zh) 2022-02-11
JP2021155433A (ja) 2021-10-07
JP2017534618A (ja) 2017-11-24
PL3209317T3 (pl) 2022-05-23
SI3209317T1 (sl) 2022-05-31
JP6989571B2 (ja) 2022-01-05
US10335452B2 (en) 2019-07-02
US20190328831A1 (en) 2019-10-31
EP3978074A1 (en) 2022-04-06
AU2015335855A1 (en) 2017-05-18
CN114028536B (zh) 2024-07-09
CN107206049A (zh) 2017-09-26
EP3209317B1 (en) 2021-12-08
HRP20220225T1 (hr) 2022-04-29

Similar Documents

Publication Publication Date Title
ES2987577T3 (es) Terlipresina para el tratamiento del síndrome hepatorrenal tipo 1
JP6962943B2 (ja) 腎不全を処置するための組成物及び方法
ES2970485T3 (es) Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares
US20240374675A1 (en) Method of treating patients with hepatorenal syndrome type 1
US20220143132A1 (en) Method of treating patients with hepatorenal syndrome type 1
US20250276033A1 (en) Compositions for improving kidney function in patients with hepatorenal syndrome
US20200237856A1 (en) Method of treating patients with hepatorenal syndrome type 1
US20210128676A1 (en) Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure
WO2022261102A1 (en) Method of treating patients with hepatorenal syndrome type 1